Please login to the form below

Not currently logged in
Email:
Password:

Votrient

This page shows the latest Votrient news and features for those working in and with pharma, biotech and healthcare.

Eisai gets green light for Lenvima in kidney cancer

Eisai gets green light for Lenvima in kidney cancer

Novartis' Votrient (pazopanib), Bayer/Onyx Nexavar (sorafenib), Pfizer's Sutent (sunitinib) or Roche's Avastin (bevacizumab).

Latest news

More from news
Approximately 2 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics